Shinko Asset Management Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Shinko Asset Management Company’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$15K	Hold	221	–	–	﹤0.01%	817
2016 Q2	$12K	Hold	221	–	–	﹤0.01%	851
2016 Q1	$14K	Hold	221	–	–	﹤0.01%	833
2015 Q4	$21K	Hold	221	–	–	﹤0.01%	763
2015 Q3	$18K	Hold	221	–	–	﹤0.01%	789
2015 Q2	$26K	Buy	+221	New	+$26.4K	﹤0.01%	642

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Shinko Asset Management Company's ALNY Position: Q3 2016 in Review

Shinko Asset Management Company held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2016 at 221 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #817.

Shinko Asset Management Company first reported a position in ALNY in Q2 2015 and has held it in 6 quarters since. The position peaked at $26K in Q2 2015. 259 funds tracked by Wall St. Rank hold ALNY as of Q3 2016.

Shinko Asset Management Company held 221 shares of Alnylam Pharmaceuticals worth $15K as of Q3 2016.
Shinko Asset Management Company left its Alnylam Pharmaceuticals share count unchanged in Q3 2016.
Alnylam Pharmaceuticals made up ﹤0.01% of Shinko Asset Management Company's portfolio in Q3 2016, its #817 holding.
Shinko Asset Management Company first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 6 quarters since.
Shinko Asset Management Company's Alnylam Pharmaceuticals position peaked at $26K in Q2 2015.
259 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2016.

Based on Shinko Asset Management Company's 13F filing for Q3 2016, filed 24 Oct 2016.